Copper and Zinc Levels in Myelodysplastic Syndrome Patients versus Healthy Subjects.
Vahid MoazedElham JafariBita RashidiNezhadBehjat Kalantari-KhandaniAli NematiAhmad Naghibzadeh TahamiForoogh MangeliPublished in: Asian Pacific journal of cancer prevention : APJCP (2020)
Overall, it can be concluded that because only a small proportion of the MDS patients enrolled in this study were found to have lower copper levels compared with the MDS patients population, further studies with a larger sample size and also clinical trials in MDS patients with serum zinc, and copper deficiency are recommended, and post-treatment hematological reassessment would also be beneficial to achieving more definitive results.